Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.34 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561472 | 0.83 | DRD1 (0.42) | CYP2A6BRD4KCNJ1DRD1ALDH1A1 | |
| SCHEMBL2028396 | 0.83 | ADH5 (0.32) | — | |
| SCHEMBL1562532 | 0.82 | DRD1 (0.41) | CYP2A6DRD1ALDH1A1 | |
| SCHEMBL1562221 | 0.82 | DRD1 (0.41) | CYP2A6DRD1ALDH1A1 | |
| Lithium SCHEMBL1562536 | 0.82 | DRD1 (0.41) | CYP2A6DRD1ALDH1A1 | |
| SCHEMBL1561381 | 0.82 | DRD1 (0.41) | CYP2A6DRD1ALDH1A1 | |
| SCHEMBL1561389 | 0.82 | DRD1 (0.41) | CYP2A6DRD1ALDH1A1 | |
| Potassium SCHEMBL1561386 | 0.82 | DRD1 (0.41) | CYP2A6DRD1ALDH1A1 | |
| SCHEMBL13411813 | 0.81 | ADH5 (0.36) | — | |
| SCHEMBL5950535 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283701-B | Compounds having the structure 4- (substituted aminomethyl) -5-neopentyl-N-substituted pyrrolidine-2-carboxamide | 中国科学院上海药物研究所 | 2025-04-22 | — | — | CN | disclosed |
| US-12173018-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-117120416-A | Small molecule compound with substituted phenyl spiro [ indoline-3, 3' -pyrrolidine ] structure | 中国科学院上海药物研究所 | 2023-11-24 | — | — | CN | disclosed |
| CN-116283701-A | Compounds having the structure 4- (substituted aminomethyl) -5-neopentyl-N-substituted pyrrolidine-2-carboxamide | 中国科学院上海药物研究所 | 2023-06-23 | — | — | CN | disclosed |
| US-11613535-B2 | Compounds for MYC inhibition | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-03-28 | — | — | US | disclosed |
| EP-3820847-B1 | IMPROVED COMPOUNDS FOR MYC INHIBITION | SCRIPPS RESEARCH INST (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-115215872-A | Small molecule compound with substituted phenyl spiro [ indoline-3, 3' -pyrrolidine ] structure | 中国科学院上海药物研究所 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022218379-A1 | SMALL-MOLECULE COMPOUND HAVING SUBSTITUTED PHENYL SPIRO[INDOLINE-3,3'-PYRROLIDINE] STRUCTURE | 中国科学院上海药物研究所 | 2022-10-20 | — | — | WO | disclosed |
| US-20220227765-A1 | PYRIDO-INDOLE ANALOGUES AS GPX4 INHIBITORS | ADRENAS THERAPEUTICS INC. | 2022-07-21 | — | — | US | disclosed |
| US-6110946-A | AN ENZYME INHIBITORS OF RETROVIRAL ASPARTATE PROTEASE FOR THE TREATMENT OF AIDS | NOVARTIS FINANCE CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0983251-A1 | ANTI-INFLAMMATORY PIPERAZINYL-BENZYL-TETRAZOLE DERIVATIVES AND INTERMEDIATES THEREOF | Pfizer Limited (GB) | 2000-03-08 | — | — | EP | disclosed |
| EP-0929553-A1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1999-07-21 | — | — | EP | disclosed |
| EP-0900210-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | Novartis AG (CH) | 1999-03-10 | — | — | EP | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1998052929-A1 | ANTI-INFLAMMATORY PIPERAZINYL-BENZYL-TETRAZOLE DERIVATIVES AND INTERMEDIATES THEREOF | PFIZER LIMITED (GB) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998014450-A1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
| WO-1997040029-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 1997-10-30 | — | — | WO | disclosed |
| US-RE32196-E | PROPHYLACTIC CHEMOTHERAPY OF ALLERGIC CONDITIONS | LILLY INDUSTRIES LIMITED (GB) | 1986-07-01 | — | — | US | disclosed |
| US-4259340-A | PROPHYLACTIC CHEMOTHERAPY OF ALLERGIC CONDITIONS SUCH AS ASTHMA | LILLY INDUSTRIES LIMITED (GB) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11613535-B2 | Compounds for MYC inhibition | MYC, MYCBP, MYCBP2 | CYP2A6 3559/4885HSD17B10 4157/4885ALDH5A1 3715/4885 |
| US-12173018-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | CYP2A6 2454/4885HSD17B10 2285/4885ALDH5A1 3327/4885 |
| US-20220227765-A1 | PYRIDO-INDOLE ANALOGUES AS GPX4 INHIBITORS | GPX4, GPX1, AIFM2 | CYP2A6 1942/4885HSD17B10 1195/4885ALDH5A1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.